TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE DRY EYE SYNDROME TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE DRY EYE SYNDROME TREATMENT MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES
3.1.2 CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET
3.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
3.1.4 RISING GERIATRIC POPULATION ACROSS THE WORLD
3.1.5 INCREASE IN LASIK SURGERY AND USAGE OF CONTACT LENSES
3.2 RESTRAINTS
3.2.1 STRINGENT REGULATORY PROCESS
3.2.2 UNMET MEDICAL NEEDS
3.3 OPPORTUNITIES
3.3.1 EMERGING MARKET PRESENTS SIGNIFICANT OPPORTUNITIES
3.3.2 DEVELOPMENT OF NOVEL TECHNOLOGIES
3.4 CHALLENGE
3.4.1 INCREASING NUMBER OF PLAYERS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 EMULSIONS
6.3 LUBRICANT EYE DROPS/SOLUTIONS
6.3.1 OILY TEAR EYE DROP
6.3.2 PRESERVATIVE-FREE DROPS
6.4 EYE OINTMENTS
6.5 NUTRITION SUPPLEMENTS
6.6 AUTOLOGOUS SERUM EYE DROPS
6.7 OTHERS
7 EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 EVAPORATIVE DRY EYE SYNDROME
7.3 AQUEOUS DRY EYE SYNDROME
8 EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 TEAR STIMULATORS
8.3 LUBRICATING AGENTS
8.4 ANTI-INFLAMMATORY DRUGS
8.5 ARTIFICIAL TEARS
8.6 ANTIBIOTIC DRUGS
8.7 OTHERS
9 EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOME HEALTHCARE
9.3 HOSPITALS
9.4 CLINICS
9.5 OTHERS
10 EUROPE DRY EYE SYNDROME TREATMENTMARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL PHARMACIES
10.3 HOSPITAL PHARMACIES
10.4 ONLINE PHARMACIES
10.5 OTHERS
11 EUROPE DRY EYE SYNDROME TREATMENT MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K.
11.1.3 FRANCE
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 NETHERLANDS
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 TURKEY
11.1.11 REST OF EUROPE
12 EUROPE DRY EYE SYNDROME TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 COMPANY PROFILES
13.1 ALLERGAN
13.1.1 COMPANY SNAPSHOT
13.1.2 COMPANY SHARE ANALYSIS
13.1.3 REVENUE ANALYSIS
13.1.4 GEOGRAPHICAL PRESENCE
13.1.5 PRODUCT PORTFOLIO
13.1.6 RECENT DEVELOPMENTS
13.2 ALCON INC
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 REVENUE ANALYSIS
13.2.4 GEOGRAPHICAL PRESENCE
13.2.5 PRODUCT PORTFOLIO
13.3 BAUSCH & LOMB INCORPORATED.
13.3.1 COMPANY SNAPSHOT
13.3.2 COMPANY SHARE ANALYSIS
13.3.3 REVENUE ANALYSIS
13.3.4 GEOGRAPHICAL PRESENCE
13.3.5 PRODUCT PORTFOLIO
13.3.6 RECENT DEVELOPMENT
13.4 NOVARTIS AG
13.4.1 COMPANY OVERVIEW
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 REVENUE ANALYSIS
13.4.4 GEOGRAPHICAL PRESENCE
13.4.5 PRODUCT PORTFOLIO
13.4.6 RECENT DEVELOPMENT
13.5 JOHNSON & JOHNSON SERVICES, INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 REVENUE ANALYSIS
13.5.4 GEOGRAPHICAL PRESENCE
13.5.5 PRODUCT PORTFOLIO
13.5.6 RECENT DEVELOPMENTS
13.6 AKORN, INCORPORATED
13.6.1 COMPANY OVERVIEW
13.6.2 REVENUE ANALYSIS
13.6.3 GEOGRAPHICAL PRESENCE
13.6.4 PRODUCT PORTFOLIO
13.6.5 RECENT DEVELOPMENT
13.7 HORUS PHARMA
13.7.1 COMPANY OVERVIEW
13.7.2 GEOGRAPHICAL PRESENCE
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 MITOTECH, SA
13.8.1 COMPANY OVERVIEW
13.8.2 GEOGRAPHICAL PRESENCE
13.8.3 PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 NOVALIQ GMBH
13.9.1 COMPANY OVERVIEW
13.9.2 GEOGRAPHICAL PRESENCE
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.10 PRESTIGE CONSUMER HEALTHCARE, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 GEOGRAPHICAL PRESENCE
13.10.4 PRODUCT PORTFOLIO
13.10.5 RECENT DEVELOPMENT
13.11 SANTEN PHARMACEUTICAL CO., LTD.
13.11.1 COMPANY OVERVIEW
13.11.2 REVENUE ANALYSIS
13.11.3 GEOGRAPHICAL PRESENCE
13.11.4 PRODUCT PORTFOLIO
13.11.5 RECENT DEVELOPMENT
13.12 SENJU PHARMACEUTICAL CO. LTD.
13.12.1 COMPANY OVERVIEW
13.12.2 REVENUE ANALYSIS
13.12.3 GEOGRAPHICAL PRESENCE
13.12.4 PRODUCT PORTFOLIO
13.12.5 RECENT DEVELOPMENT
13.13 SIMILASAN
13.13.1 COMPANY OVERVIEW
13.13.2 GEOGRAPHICAL PRESENCE
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENT
13.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 GEOGRAPHICAL PRESENCE
13.14.4 PRODUCT PORTFOLIO
13.14.5 RECENT DEVELOPMENTS
13.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 GEOGRAPHICAL PRESENCE
13.15.4 PRODUCT PORTFOLIO
13.15.5 RECENT DEVELOPMENT
13.16 VISUFARMA
13.16.1 COMPANY OVERVIEW
13.16.2 GEOGRAPHICAL PRESENCE
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS